Close

GSK to acquire 25% stake in Aspen Japan

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

British drug maker GlaxoSmithKline (GSK) has signed an agreement with Aspen Global (AGI) to acquire interest in its newly established subsidiary Aspen Japan.

As part of the deal, GSK will acquire a 25% interest in Aspen Japan, while the remaining stake will be owned by Aspen.

The agreement will allow Aspen Japan to carry out its commercial operations in the country through a strategic alliance with GSK.

AGI will transfer the marketing authorisations and grant perpetual distribution rights to Aspen Japan for all products.

In accordance with the collaboration, AGI will transfer the marketing authorisations and grant perpetual distribution rights to Aspen Japan for all products, which are presently being marketed and supplied on behalf of Aspen in Japan.

GSK will also transfer the marketing authorisations and grant distribution rights to Aspen Japan for certain mature products in its portfolio.

In addition, GSK will provide a pipeline of authorised generics for its multiple products to Aspen Japan, while AGI will offer the rights of all future products, which it acquires or licenses in Japan.

AGI will take care of the management of Aspen Japan, as well as commercialisation of all the products in its portfolio.

Completion of the deal is subject to multiple conditions, including Aspen Japan obtaining accreditation as a marketing authorisation holder from the relevant Japanese regulatory authority.

Latest stories

Related stories

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back